Proxy Biomedical, an Ireland-based design, development and manufacturing firm supporting biomaterial product solutions for medical implants, announced a substantial facility expansion due for completion in 2Q16.
The expansion is the result of new business and continued revenue growth supported by the 2015 launch of solutions such as Proxy Bio-XT, a proprietary process that reinforces resorbable implants for applications such as soft tissue fixation in sports medicine and orthopaedics.
The company will double cleanroom manufacturing facilities, introducing a suite of new technologies and biomaterial conversion processes.
In 2016, Proxy Biomedical expects to expand its solutions portfolio for resorbable biomaterials in textiles and solid implants. Pre-clinical trials are scheduled to evaluate innovative antimicrobial implantable materials, while the company's coating capabilities are set for further expansion.
Source: Proxy Biomedical, Ltd.
Bio-XT is a strength-enhancing proprietary processing technology used to form non-metallic medical implants, such as orthopaedic screws. It launched in late 3Q15.
Niall Rooney, Ph.D., Director of Business Development at Proxy, detailed the Bio-XT's advantages, limitations and thoughts on the future of resorbables in BONEZONE, "Materials in Motion."